Using metformin to improve fibromyalgia symptoms
Official title: Metformin as a Novel, Mechanistic Treatment of Fibromyalgia; a Proof of Concept RCT
Run by University of Utah · NCT05900466 · Data updated 2026-11-12
This study is testing if low-dose metformin can help people with fibromyalgia feel better compared to a placebo.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 72 (estimated) |
| Sponsor | University of Utah Academic / other |
| Locations | 1 site (Salt Lake City, Utah) |
| Status | Recruiting |
| Started | April 1, 2023 |
| Main results expected | March 31, 2027 |
| Study ends | March 31, 2027 |
| Registry record updated | March 30, 2026 |
| Trial ID | NCT05900466 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults diagnosed with fibromyalgia syndrome who meet specific classification criteria and can adhere to a medication regimen.
✕Probably not a fit
Patients with co-occurring progressive diseases, diabetes, or serious psychopathology may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to evaluate the safety and efficacy of low-dose metformin in improving symptoms associated with fibromyalgia syndrome (FMS). The study hypothesizes that patients receiving metformin will experience greater symptom relief compared to those on a placebo. The approach focuses on modulating neuroinflammatory pathways, which are believed to contribute to the chronic pain experienced by FMS patients. By targeting these pathways, the study seeks to provide a more effective treatment option for a condition that currently has limited therapeutic success.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the quality of life for patients suffering from fibromyalgia by alleviating their symptoms more effectively than current therapies.
How similar studies have gone: While the use of metformin for fibromyalgia is a novel approach, preclinical studies have shown promise in treating related symptoms, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * To be able to follow the protocol in English * Fibromyalgia Syndrome: Participant must meet the American College of Rheumatology 2016 revised classification criteria for Fibromyalgia * Ability to take oral medication and be willing to adhere to the metformin regimen (once daily) Exclusion Criteria: * Co-occurring progressive disease (self-report, physician-diagnosed) * Diabetes * Pregnancy or planning to be pregnant in the next year (all premenopausal participants will be tested) * Having known cardiovascular, liver, kidney or pulmonary diseases (self-report, physician-diagnosed) * Having known serious psychopathology (Clinician diagnoses of psychosis, organic mental disorder, or dissociative disorder, self-reported active suicidal intent, self-reported history of inpatient admission to a psychiatric ward in the past year, evidence or self-report of self-injurious behaviors in the past year, reported current or recent history (2years) of non-IV substance abuse, any history of recreational IV drug use) * Having autoimmune disorder (e.g., rheumatoid arthritis) (self-report, physician-diagnosed) * Having neuropathic pain (self-report, physician-diagnosed) * Having pain associated with a terminal illness, acute pain, pain associated with specific organ damage (eg, stomach ulcer) (self-report, physician-diagnosed) * Concurrent use of weight controlling medications (eg, Xenical) * Requiring an interpreter to communicate * Abnormal levels of creatinine, vitamin B12, or hepatic function panel * eGFR of below 45mL/min/1.73m2
Where it's running
-
University of Utah
Salt Lake City, Utah, United States Recruiting
Study contacts
- Principal investigator: Akiko Okifuji, PhD — University of Utah
- Study coordinator: Reiko Mitsunaga, RN
- Email: reiko.mitsunaga@hsc.utah.edu
- Phone: 801-585-7695
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Yangyin Roujin Formula for Fibromyalgia: Does it help pain and function?
A randomized, double-blind study tests whether Yangyin Roujin Decoction can ease pain and improve function for adults with fibromyalgia compared with a placebo.
-
Transcutaneous Vagus Nerve Stimulation for Fibromyalgia Pain and Autonomic Dysfunction
This study tests a non-invasive nerve stimulation method to see if it helps people with fibromyalgia who have widespread pain and autonomic symptoms.
-
Auricular acupuncture to balance autonomic function and pain in fibromyalgia
This study tests whether semi-permanent ear acupuncture can improve autonomic regulation and pain sensitivity in adult women with fibromyalgia over five weeks.
-
Yishen Shujin Decoction for adults with fibromyalgia.
This 24-week randomized, double-blind, placebo-controlled trial will test whether Yishen Shujin Decoction reduces pain and improves symptoms in adults with fibromyalgia.
-
Effect of raising a child with ADHD on mothers' fibromyalgia burden
We will see if mothers aged 18–50 who have fibromyalgia and a child with ADHD have more disease burden than mothers with fibromyalgia whose children do not have psychiatric disorders.
-
Forward head posture and symptom severity in fibromyalgia
See if forward head posture, measured by the craniovertebral angle, is linked to symptom severity in adults aged 18–55 with fibromyalgia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.